Our paper on “The Mutational Footprints of Cancer Therapies” is out in .
A look at mutational signatures of widely used anticancer therapies across 3,500 metastatic tumors from different organs
A very under-studied yet important consequence of #cancer therapies: the mutations they induce by and their colleagues
a study of the mutational signatures induced by cispl, oxalipl, carbopl, gemcit, capecit or 5FU across >3,500 met tumors across ~20 different origins reveals that these drugs induce mutational burden, eventually leading to 2nd malignancies
🧬 Check out this amazing piece of work published in “The mutational footprints of cancer therapies” by Pich et al. 💊 Link:
Remarkable paper describing mutational signatures for widely used anticancer therapies in >3,500 metastatic tumors. Treatment-associated signatures were enriched for late variants relative to those accumulated during tumor evolution:
The mutational footprints of cancer therapies
The mutational footprints of cancer therapies | Nature Genetics
The mutational footprints of cancer therapies via et al
Analysis of whole-genome sequences from more than 3,500 metastatic tumors identifies mutational signatures associated with different chemotherapies and provides estimates of the relative contribution of different treatments to tumor mutational burden.
The mutational footprints of cancer therapies, by lab.